Moderna (MRNA) Capital Leases (2017 - 2026)

Moderna (MRNA) has 10 years of Capital Leases data on file, last reported at $13.0 million in Q1 2026.

• Capital Leases for Q1 2026 came in at $13.0 million, down 62.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (down 62.86% YoY), and the FY2025 annual result was $20.0 million, down 48.72% from the prior year.
• Capital Leases retreated to $13.0 million in Q1 2026 per MRNA's latest filing, from $20.0 million in the prior quarter.
• Over five years, Capital Leases peaked at $922.0 million in Q3 2022 and troughed at $13.0 million in Q1 2026.
• A 5-year average of $463.9 million and a median of $575.0 million in 2023 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2022 and 2025: Capital Leases soared 368.12% in 2022, then slumped 95.84% in 2025.
• A 5-year view of Capital Leases shows it stood at $912.0 million in 2022, then plunged by 36.95% to $575.0 million in 2023, then plunged by 93.22% to $39.0 million in 2024, then slumped by 48.72% to $20.0 million in 2025, then tumbled by 35.0% to $13.0 million in 2026.
• Business Quant data shows MRNA's Capital Leases at $13.0 million in Q1 2026, $20.0 million in Q4 2025, and $26.0 million in Q3 2025.